Retinal upregulation of inflammatory and proangiogenic markers in a model of neonatal diabetic rats fed on a high-fat-diet

BMC Ophthalmology

Volumn 13, Issue 1, 2013, Pages

  Mancini, Jorge E ^a   Ortiz, Gustavo ^a   Croxatto, Juan Oscar ^b   Gallo, Juan E ^a  

^a UNIVERSIDAD AUSTRAL   (Argentina)

^b Fundacion Oftalmologica Argentina Jorge Malbran   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCOSYLATION END PRODUCT RECEPTOR; ADVANCED GLYCOSYLATION END-PRODUCT RECEPTOR; BIOLOGICAL MARKER; GLIAL FIBRILLARY ASTROCYTIC PROTEIN, MOUSE; IMMUNOGLOBULIN RECEPTOR; NERVE PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL; ARTICLE; CHEMICALLY INDUCED DISORDER; CYTOLOGY; DIABETIC RETINOPATHY; EXPERIMENTAL DIABETES MELLITUS; LIPID DIET; METABOLISM; PATHOLOGY; PERICYTE; RAT; RETINA; RETINA GANGLION CELL; UPREGULATION; WISTAR RAT; CHEMICALLY INDUCED;

ANIMALS; BIOLOGICAL MARKERS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC RETINOPATHY; DIET, HIGH-FAT; NERVE TISSUE PROTEINS; PERICYTES; RATS; RATS, WISTAR; RECEPTORS, IMMUNOLOGIC; RETINA; RETINAL GANGLION CELLS; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 84876147255     PISSN: None     EISSN: 14712415     Source Type: Journal    
DOI: 10.1186/1471-2415-13-14     Document Type: Article

References (50)

1. Unraveling the causes of diabetes. Marx J, Science 2002 296 5568 686 689 10.1126/science.296.5568.686 11976439 (Pubitemid 34441985)
2. Changing habits to delay diabetes. Tataranni PA, Bogardus C, N Engl J Med 2001 344 18 1390 1392 11333998 (Pubitemid 32378396)
3. Prevalence of impaired glucose tolerance among children and adolescents with marked obesity. Sinha R, Fisch G, Teague B, Tamborlane WV, Banyas B, Allen K, et al. N Engl J Med 2002 346 11 802 810 10.1056/NEJMoa012578 11893791 (Pubitemid 34984653)
4. Facing the diabetes epidemic-mandatory reporting of glycosylated hemoglobin values in New York City. Steinbrook R, N Engl J Med 2006 354 6 545 548 10.1056/NEJMp068008 16467539 (Pubitemid 43209099)
5. Epidemiology of diabetes. Winer N, Sowers JR, J Clin Pharmacol 2004 44 4 397 405 10.1177/0091270004263017 15051748 (Pubitemid 38396785)
6. Early retinal damage in experimental diabetes: electroretinographical and morphological observations. Li Q, Zemel E, Miller B, Perlman I, Exp Eye Res 2002 74 5 615 625 10.1006/exer.2002.1170 12076083 (Pubitemid 34757017)
7. A simplified diabetic retinopathy scale. Chew EY, Ophthalmology 2003 110 9 1675 1676 10.1016/S0161-6420(03)00815-7 13129860 (Pubitemid 37025421)
8. Retinal neovascularisation without ischaemia in the spontaneously diabetic Torii rat. Yamada H, Yamada E, Higuchi A, Matsumura M, Diabetologia 2005 48 8 1663 1668 10.1007/s00125-005-1809-0 15977012 (Pubitemid 41175521)
9. Responses of neonatal rat islets to streptozotocin: limited B-cell regeneration and hyperglycemia. Bonner-Weir S, Trent DF, Honey RN, Weir GC, Diabetes 1981 30 1 64 69 10.2337/diabetes.30.1.64 6112177 (Pubitemid 11022626)
10. Inducement by fat feeding of basal hyperglycemia in rats with abnormal beta-cell function. Model for study of etiology and pathogenesis of NIDDM. Pascoe WS, Storlien LH, Diabetes 1990 39 2 226 233 10.2337/diabetes.39.2.226 2146180 (Pubitemid 20054291)
11. Dyslipidemia-Induced Adhesion Molecule Expression in hRVE Cell. Chen WJD, Grant MB, Esselman JE, Busik JV, Invest Ophthalmol Vis Sci 2003 44 11 5016 5022 10.1167/iovs.03-0418 14578429 (Pubitemid 37315320)
12. Insulin action and determinants of glycaemia in a rat model of type 2 (non-insulin-dependent) diabetes mellitus. Pascoe WS, Jenkins AB, Kusunoki M, Storlien LH, Diabetologia 1992 35 3 208 215 10.1007/BF00400919 1563580
13. Islet secretion in a new experimental model for non-insulin-dependent diabetes. Weir GC, Clore ET, Zmachinski CJ, Bonner-Weir S, Diabetes 1981 30 7 590 595 10.2337/diabetes.30.7.590 6114005 (Pubitemid 11026632)
14. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Bradford MM, Anal Biochem 1976 72 248 254 10.1016/0003-2697(76)90527-3 942051
15. Studies of retinal vascular patterns. I. Normal architecture. Kuwabara T, Cogan DG, Arch Ophthalmol 1960 64 904 911 10.1001/archopht.1960.01840010906012 13755464
16. Insulin binding and glucose transport in adipocytes in neonatal streptozocin-injected rat model of diabetes mellitus. Fantus IG, Chayoth R, O'Dea L, Marliss EB, Yale JF, Grose M, Diabetes 1987 36 5 654 660 10.2337/diabetes.36.5.654 3552798 (Pubitemid 18024743)
17. Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: a model for type 2 diabetes and pharmacological screening. Srinivasan K, Viswanad B, Asrat L, Kaul CL, Ramarao P, Pharmacol Res 2005 52 4 313 320 10.1016/j.phrs.2005.05.004 15979893 (Pubitemid 41175991)
18. Dyslipidemia: evidence of efficacy of the pharmacological and non-pharmacological treatment in the elderly. Gravina CF, Bertolami M, Rodrigues GH, J Geriatr Cardiol 2012 9 2 83 90 10.3724/SP.J.1263.2011.12292 22916052
19. Mamelle N, al e. Mediterranean alpha-linoleic acid-rich diet in secondary prevention of coronary heart disease. De Lorgeril M, Renaud S, Lancet 1994 343 1454 1459 10.1016/S0140-6736(94)92580-1 7911176 (Pubitemid 24176333)
20. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lion Diet Heart Study. De Lorgeril M, Salen P, Martin JM, Monjaud I, Delaye J, Mamelle N, Circulation 1999 99 779 785 10.1161/01.CIR.99.6.779 9989963 (Pubitemid 29083018)
21. Dietary intake of long-chain n-3 polynsaturated fatty acids and the of primary cardiac arrest. Siscovick DS, Raghunathan T, King I, et al. Am J Clin Nutr 2000 71 208 212
22. Survival signaling in retinal pigment epithelial cells in response to oxidative stress: significance in retinal degenerations. Bazan NG, Adv Exp Med Biol 2006 572 531 540 10.1007/0-387-32442-9-74 17249620
23. Cell survival matters: docosahexaenoic acid signaling, neuroprotection and photoreceptors. Bazan N, Trends Neurosci 2006 29 5 263 271 10.1016/j.tins.2006.03.005 16580739
24. A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease. Lukiw WJ, Cui JG, Marcheselli VL, Bodker M, Botkjaer A, Gotlinger K, et al. J Clin Invest 2005 115 10 2774 2783 10.1172/JCI25420 16151530 (Pubitemid 41434404)
25. Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Samuelsson B, Dahlen SE, Lindgren JA, Rouzer CA, Serhan CN, Science 1987 237 4819 1171 1176 10.1126/science.2820055 2820055 (Pubitemid 17131222)
26. Increased synthesis of leukotrienes in the mouse model of diabetic retinopathy. Talahalli R, Zarini S, Sheibani N, Murphy RC, Gubitosi-Klug RA, Invest Ophthalmol Vis Sci 2010 51 3 1699 1708 10.1167/iovs.09-3557 19834040
27. Leukotriene B4 enhances the activity of nuclear factor-kappaB pathway through BLT1 and BLT2 receptors in atherosclerosis. Sanchez-Galan E, Gomez-Hernandez A, Vidal C, Martin-Ventura JL, Blanco-Colio LM, Munoz-Garcia B, et al. Cardiovasc Res 2009 81 1 216 225 10.1093/cvr/cvn277 18852255
28. AGEs, RAGE, and diabetic retinopathy. Zong H, Ward M, Stitt AW, Curr Diab Rep 2011 11 4 244 252 10.1007/s11892-011-0198-7 21590515
29. Cardioprotective effect of 5-lipoxygenase gene (ALOX5) silencing in ischemia-reperfusion. Lisovyy OO, Dosenko VE, Nagibin VS, Tumanovska LV, Korol MO, Surova OV, et al. Acta Biochim Pol 2009 56 4 687 694 20011686
30. New insights into the retinal circulation: inflammatory lipid mediators in ischemic retinopathy. Hardy P, Beauchamp M, Sennlaub F, Gobeil F Jr, Tremblay L, Mwaikambo B, et al. Prostaglandins Leukot Essent Fatty Acids 2005 72 5 301 325 10.1016/j.plefa.2005.02.004 15850712 (Pubitemid 40590052)
31. 5-Lipoxygenase, but not 12/15-lipoxygenase, contributes to degeneration of retinal capillaries in a mouse model of diabetic retinopathy. Gubitosi-Klug RA, Talahalli R, Du Y, Nadler JL, Kern TS, Diabetes 2008 57 5 1387 1393 10.2337/db07-1217 18346986
32. Short communication: PPAR gamma mediates a direct antiangiogenic effect of omega 3-PUFAs in proliferative retinopathy. Stahl A, Sapieha P, Connor KM, Sangiovanni JP, Chen J, Aderman CM, et al. Circ Res 2010 107 4 495 500 10.1161/CIRCRESAHA.110.221317 20634487
33. 5-Lipoxygenase metabolite 4-HDHA is a mediator of the antiangiogenic effect of omega-3 polyunsaturated fatty acids. Sapieha P, Stahl A, Chen J, Seaward MR, Willett KL, Krah NM, et al. Sci Transl Med 2011 3 69 69ra12 10.1126/scitranslmed.3001571 21307302
34. The 5-lipoxygenase inhibitor, zileuton, suppresses prostaglandin biosynthesis by inhibition of arachidonic acid release in macrophages. Rossi A, Pergola C, Koeberle A, Hoffmann M, Dehm F, Bramanti P, et al. Br J Pharmacol 2010 161 3 555 570 10.1111/j.1476-5381.2010.00930.x 20880396
35. Inhibition of diabetic leukostasis and blood-retinal barrier breakdown with a soluble form of a receptor for advanced glycation end products. Kaji Y, Usui T, Ishida S, Yamashiro K, Moore TC, Moore J, et al. Invest Ophthalmol Vis Sci 2007 48 2 858 865 10.1167/iovs.06-0495 17251488 (Pubitemid 351260723)
36. Receptor for advanced glycation end products is involved in impaired angiogenic response in diabetes. Shoji T, Koyama H, Morioka T, Tanaka S, Kizu A, Motoyama K, et al. Diabetes 2006 55 8 2245 2255 10.2337/db05-1375 16873687 (Pubitemid 44743621)
37. Advanced glycation end products (AGEs) and their receptor (RAGE) system in diabetic retinopathy. Yamagishi S, Nakamura K, Matsui T, Curr Drug Discov Technol 2006 3 1 83 88 10.2174/157016306776637555 16712466
38. Muller cell changes in human diabetic retinopathy. Mizutani M, Gerhardinger C, Lorenzi M, Diabetes 1998 47 3 445 449 10.2337/diabetes.47.3.445 9519752 (Pubitemid 28104208)
39. Muller cell-derived VEGF is essential for diabetes-induced retinal inflammation and vascular leakage. Wang J, Xu X, Elliott MH, Zhu M, Le YZ, Diabetes 2010 59 9 2297 2305 10.2337/db09-1420 20530741
40. Pigment epithelium-derived factor (PEDF) is an endogenous antiinflammatory factor. Zhang SX, Wang JJ, Gao G, Shao C, Mott R, Ma JX, FASEB J 2006 20 2 323 325 16368716 (Pubitemid 46671158)
41. Tumor-surrogate blood vessel subtypes exhibit differential susceptibility to anti-VEGF therapy. Sitohy B, Nagy JA, Jaminet SC, Dvorak HF, Cancer Res 2011 71 22 7021 7028 10.1158/0008-5472.CAN-11-1693 21937680
42. Pharmacokinetic Rationale for Dosing Every 2 Weeks Versus 4 Weeks with Intravitreal Ranibizumab, Bevacizumab, and Aflibercept (Vascular Endothelial Growth Factor Trap-Eye). Stewart MW, Rosenfeld PJ, Penha FM, Wang F, Yehoshua Z, Bueno-Lopez E, et al. Retina 2012 32 3 434 457 22374154
43. TNFalpha is required for late BRB breakdown in diabetic retinopathy, and its inhibition prevents leukostasis and protects vessels and neurons from apoptosis. Huang H, Gandhi JK, Zhong X, Wei Y, Gong J, Duh EJ, et al. Invest Ophthalmol Vis Sci 2011 52 3 1336 1344 10.1167/iovs.10-5768 21212173
44. Comparative efficacy of biologics in psoriasis: a review. Kim IH, West CE, Kwatra SG, Feldman SR, O'Neill JL, Am J Clin Dermatol 2012 13 6 365 374 10.2165/11633110-000000000-00000 22967166
45. Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study. Weinblatt ME, Fleischmann R, Huizinga TW, Emery P, Pope J, Massarotti EM, et al. Rheumatology (Oxford) 2012 51 12 2204 2214 10.1093/rheumatology/ kes150
46. Tumor necrosis factor and its receptors in the neuroretina and retinal vasculature after ischemia-reperfusion injury in the pig retina. Gesslein B, Hakansson G, Gustafsson L, Ekstrom P, Malmsjo M, Mol Vis 2010 16 2317 2327 21152396
47. Dual inhibition of sphingosine kinase isoforms ablates TNF-induced drug resistance. Antoon JW, White MD, Burow ME, Beckman BS, Oncol Rep 2012 27 6 1779 1786 22469881
48. Tumor necrosis factor-alpha-stimulated cell proliferation is mediated through sphingosine kinase-dependent Akt activation and cyclin D expression. Seasholtz TM, Chang J, Smith J, Walsh C, Brown J, Radeff-Huang j, J Biol Chem 2007 282 863 870 17114809 (Pubitemid 47076562)
49. Profile of lipid and protein autacoids in diabetic vitreous correlates with the progression of diabetic retinopathy. Schwartzman ML, Iserovich P, Gotlinger K, Bellner L, Dunn MW, Sartore M, et al. Diabetes 2010 59 7 1780 1788 10.2337/db10-0110 20424229
50. Effects of bevacizumab plus irinotecan on response and survival in patients with recurrent malignant glioma: a systematic review and survival-gain analysis. Xu T, Chen J, Lu Y, Wolff JE, BMC Cancer 2010 10 252 10.1186/1471-2407-10-252 20525214